![]() | |
Clinical data | |
---|---|
Trade names | Terlivaz |
AHFS/Drugs.com | International Drug Names |
Routes of administration | Intravenous |
ATC code | |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Protein binding | ~30% |
Identifiers | |
| |
CAS Number | |
PubChem CID | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.035.149 |
Chemical and physical data | |
Formula | C52H74N16O15S2 |
Molar mass | 1227.38 g·mol−1 |
3D model (JSmol) | |
| |
| |
(verify) |
Terlipressin, sold under the brand name Terlivaz among others, is an analogue of vasopressin used as a vasoactive drug in the management of low blood pressure. It has been found to be effective when norepinephrine does not help. Terlipressin is a vasopressin receptor agonist. [2]
Terlipressin was approved for medical use in the United States in 2022. [2] [4] [5] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication. [5] [6]
Terlipressin is indicated to improve kidney function in adults with hepatorenal syndrome with rapid reduction in kidney function. [2]
Indications for use include norepinephrine-resistant septic shock [7] although, 2021 Surviving Sepsis Guidelines recommend against its use for adults with septic shock [8] and hepatorenal syndrome. [9] In addition, it is used to treat bleeding esophageal varices. [10]
Terlipressin is contraindicated in people experiencing hypoxia or worsening respiratory symptoms and in people with ongoing coronary, peripheral or mesenteric ischemia. [2] Terlipressin may cause fetal harm when used during pregnancy. [2]
Terlipressin is available in United States, [11] New Zealand, [12] Australia, the European Union, [13] India, Pakistan & UAE. It is sold under various brand names including Glypressin and Terlivaz.